Our ******* ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Organic revenue growth accelerated to 6% year-over-year, tripling the rate from the prior year due to improving market conditions and strong operational execution.
The R&D Solutions segment benefited from a consistently improving demand environment and higher win rates, particularly within the Emerging Biopharma (EBP) segment which now represents 70% of global clinical trial starts.
Commercial Solutions growth was fueled by a 45% increase in new drug launches in the first half of 2026, driving demand for ******* ytics, consulting, and patient solutions.
Management highlighted a strategic shift in large pharma toward outsourcing full commercialization of therapies in select geographies, where IQVIA is capturing significant market share.
#year #segment #NVIDIA #tell
Organic revenue growth accelerated to 6% year-over-year, tripling the rate from the prior year due to improving market conditions and strong operational execution.
The R&D Solutions segment benefited from a consistently improving demand environment and higher win rates, particularly within the Emerging Biopharma (EBP) segment which now represents 70% of global clinical trial starts.
Commercial Solutions growth was fueled by a 45% increase in new drug launches in the first half of 2026, driving demand for ******* ytics, consulting, and patient solutions.
Management highlighted a strategic shift in large pharma toward outsourcing full commercialization of therapies in select geographies, where IQVIA is capturing significant market share.
#year #segment #NVIDIA #tell
3 months ago
